Bicycle Therapeutics

Bicycle Therapeutics company information, Employees & Contact Information

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company that is harnessing the power of bicyclic peptides and leveraging Nobel Prize-winning science to develop a new and differentiated class of medicines to treat cancer and other diseases. Bicycle® molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin, previously BT8009, a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radio Conjugates (BRC™) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, MA.

Company Details

Employees
344
Founded
-
Address
Granta Park, Cambridge,england Cb21 6gp,united Kingdom
Phone
44 1223 497 415
Email
in****@****ics.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Cambridge, England
Looking for a particular Bicycle Therapeutics employee's phone or email?

Bicycle Therapeutics Questions

News

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results - Business Wire

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results Business Wire

Bicycle lays off 25% of workforce as Genentech rides away from R&D pact - Fierce Biotech

Bicycle lays off 25% of workforce as Genentech rides away from R&D pact Fierce Biotech

Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones - Yahoo Finance

Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones Yahoo Finance

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire

Cambridge cancer biotech cuts 25% of workforce - The Business Journals

Cambridge cancer biotech cuts 25% of workforce The Business Journals

Bicycle Therapeutics: Maybe Underwhelming, But I Don't Think They Should Be This Discounted - Seeking Alpha

Bicycle Therapeutics: Maybe Underwhelming, But I Don't Think They Should Be This Discounted Seeking Alpha

Bicycle Therapeutics Strengthens Board of Directors with New Appointments - Business Wire

Bicycle Therapeutics Strengthens Board of Directors with New Appointments Business Wire

Bicycle Therapeutics - Business Weekly

Bicycle Therapeutics Business Weekly

Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology - Bayer

Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology Bayer

Bicycle Therapeutics: Trading At Cash, Underwhelming But Not Unsalvageable Data (BCYC) - Seeking Alpha

Bicycle Therapeutics: Trading At Cash, Underwhelming But Not Unsalvageable Data (BCYC) Seeking Alpha

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results - citybiz

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results citybiz

Phase 2/3 study launching of targeted therapy BT8009 in urothelial carcinoma - Urology Times

Phase 2/3 study launching of targeted therapy BT8009 in urothelial carcinoma Urology Times

Bicycle Therapeutics - The Pharma Letter

Bicycle Therapeutics The Pharma Letter

Bicycle Therapeutics plc (NASDAQ:BCYC) has caught the attention of institutional investors who hold a sizeable 45% stake - Yahoo Finance

Bicycle Therapeutics plc (NASDAQ:BCYC) has caught the attention of institutional investors who hold a sizeable 45% stake Yahoo Finance

Bicycle Therapeutics scores $555M investment for disease prevention - Tech.eu

Bicycle Therapeutics scores $555M investment for disease prevention Tech.eu

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results - Business Wire

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results Business Wire

Bicycle Therapeutics Appoints Jose-Carlos Gutierrez-Ramos, Ph.D., to its Board of Directors - citybiz

Bicycle Therapeutics Appoints Jose-Carlos Gutierrez-Ramos, Ph.D., to its Board of Directors citybiz

Bicycle Therapeutics Boosts Balance Sheet To Navigate Data Desert (NASDAQ:BCYC) - Seeking Alpha

Bicycle Therapeutics Boosts Balance Sheet To Navigate Data Desert (NASDAQ:BCYC) Seeking Alpha

Bicycle Therapeutics Announces New Board and Key Clinical Leadership Appointments - Business Wire

Bicycle Therapeutics Announces New Board and Key Clinical Leadership Appointments Business Wire

How can we target emerging oligonucleotide therapies for success? - drugdiscoverytrends.com

How can we target emerging oligonucleotide therapies for success? drugdiscoverytrends.com

Bicycle Therapeutics (BCYC) Stock Price, News & Analysis - MarketBeat

Bicycle Therapeutics (BCYC) Stock Price, News & Analysis MarketBeat

Top Bicycle Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant